Eli Lilly and Company (NYSE:LLY) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,779 shares of the company’s stock after selling 803 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Eli Lilly and Company were worth $11,992,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fairfield Bush & CO. bought a new stake in Eli Lilly and Company in the first quarter worth about $107,000. Roundview Capital LLC raised its holdings in shares of Eli Lilly and Company by 2.6% in the 1st quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock worth $589,000 after purchasing an additional 53 shares in the last quarter. Merit Financial Group LLC acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $210,000. NewEdge Advisors LLC boosted its holdings in Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after buying an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in Eli Lilly and Company in the first quarter worth approximately $561,000. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Alonzo Weems sold 1,148 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $590.98, for a total transaction of $678,445.04. Following the transaction, the executive vice president now owns 7,760 shares in the company, valued at $4,586,004.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Alonzo Weems sold 1,148 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total transaction of $678,445.04. Following the completion of the sale, the executive vice president now directly owns 7,760 shares of the company’s stock, valued at approximately $4,586,004.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at $2,939,130.78. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,010,309 shares of company stock worth $21,095,701,670. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

NYSE LLY opened at $598.88 on Thursday. The company has a 50 day moving average price of $504.85 and a two-hundred day moving average price of $433.48. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.13. The stock has a market capitalization of $568.51 billion, a PE ratio of 83.29, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.13. The business had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a return on equity of 65.00%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.25 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 9.83 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s payout ratio is 62.87%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 9th. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $630.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 5th. HSBC assumed coverage on shares of Eli Lilly and Company in a research report on Friday, July 14th. They issued a “buy” rating and a $560.00 target price on the stock. Finally, Truist Financial upped their price target on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.